FDA Section 361 Compliance Checklist for Allografts

A clinical FDA Section 361 compliance checklist for purchasing human tissue allografts centers on validating an active FDA Establishment Identifier (FEI), inspecting lot-specific Certificates of Analysis, and archiving donor eligibility records before accepting inventory. Implementing these chain-of-custody controls protects practices from purchasing misbranded or adulterated biologics that fail current Good Tissue Practice standards under 21 CFR 1271. Review this step-by-step procurement framework to audit prospective tissue banks, verify cold-chain logs, and establish inspection-ready clinic binder protocols.

Understanding the Regulatory Landscape: Section 361 vs. Section 351

For medical practice administrators managing procurement for regenerative medicine or orthopedic practices, understanding the distinction between Section 361 and Section 351 of the Public Health Service (PHS) Act is foundational to risk management. Human cells, tissues, and cellular and tissue-based products (HCT/Ps) are regulated by the FDA under 21 CFR Part 1271.

Products regulated solely under Section 361 do not require premarket approval or a Biologics License Application (BLA) because they meet specific criteria designed to minimize clinical and communicable disease risk. Conversely, if a human tissue product fails to meet even one of the four criteria in 21 CFR 1271.10(a), it transitions into the Section 351 category. Section 351 products are regulated as drugs, devices, or biological products and require an Investigational New Drug (IND) application for clinical trials or an approved BLA before they can be legally marketed and distributed.

When evaluating biologics such as amniotic membrane allografts, Wharton’s Jelly, or cord blood products, the operational burden falls on both the supplier and the purchasing clinic to ensure the product is lawfully marketed. Relying solely on a sales representative's verbal assurance is insufficient; administrators must build a documented due diligence file for every biological product entering the facility.

The FDA Section 361 Compliance Checklist for Practice Managers

When vetting a tissue bank or medical distributor, practice managers should systematically work through the following procurement checklist and store the resulting documentation in a dedicated compliance binder or digital repository.

1. Verify FDA Establishment Registration

• Confirm Active Status: Use the FDA’s Human Cell and Tissue Establishment Registration (HCTER) public database to confirm the manufacturing tissue bank holds an active registration.
• Check Product Listings: Ensure the specific HCT/P categories (e.g., amniotic membrane, umbilical cord) you intend to purchase are explicitly listed under the manufacturer’s registration profile.
• Review Inspection History: Request information regarding the facility's most recent FDA inspection. Verify whether any Form 483 observations or Warning Letters have been issued, and if so, request the documented corrective action plans.

2. Audit the Four Regulatory Criteria (21 CFR 1271.10(a))

• Minimal Manipulation: For structural tissue, confirm that processing does not alter the original relevant characteristics of the tissue relating to its utility for reconstruction, repair, or replacement. For cells or nonstructural tissues, confirm processing does not alter relevant biological characteristics.
• Homologous Use: Review the manufacturer’s package insert and promotional literature. The intended use must perform the same basic function or functions in the recipient as in the donor (such as serving as a protective covering or structural barrier).
• No Combination with Prohibited Articles: Confirm the tissue is not combined with another article, aside from water, crystalloids, or a sterilizing, preserving, or storing agent.
• Systemic Effect Profile: Confirm the HCT/P does not depend upon the metabolic activity of living cells for its primary function, unless it is intended for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.

3. Validate Donor Eligibility and Screening Standards

• Infectious Disease Testing: Require a sample Certificate of Analysis (CoA) or tissue release record demonstrating that donor blood specimens were tested using FDA-licensed, approved, or cleared donor screening tests for relevant communicable disease agents (including HIV, Hepatitis B, Hepatitis C, and syphilis).
• AATB Accreditation: While not a federal requirement, accreditation by the American Association of Tissue Banks (AATB) indicates that the processing facility adheres to rigorous industry standards for tissue recovery, processing, and quality assurance.
• Sterility and Endotoxin Testing: Verify whether each lot undergoes USP <71> sterility testing and endotoxin testing prior to final release.

4. Cold Chain Logistics and Facility Workflow

• Shipping Validation: Confirm that the vendor uses validated shipping containers (dry ice or liquid nitrogen dry shippers) capable of maintaining required temperatures beyond the expected transit window.
• Receiving Protocols: Establish internal standard operating procedures (SOPs) for staff to inspect package integrity, verify remaining coolant upon arrival, and log lot numbers immediately into the clinic’s inventory system.
• Adverse Event Reporting: Ensure the vendor provides a clear mechanism for tissue tracking (from donor to recipient) and reporting any suspected adverse reactions or communicable disease transmissions.

Clinical Considerations for the Treating Physician

While practice administrators focus on vendor qualification, audit readiness, and supply chain integrity, the treating physician approaches HCT/P procurement from a clinical utility and compliance perspective. Both roles must align to protect the practice.

For clinicians integrating allografts alongside regenerative modalities—such as extracorporeal shockwave therapy or high-power laser systems found in our devices portfolio—clinical charting and patient communication are critical compliance touchpoints. Physicians must understand that how a product is marketed and explained to patients impacts its regulatory classification. Even if a tissue bank processes an amniotic or Wharton’s Jelly allograft within minimal manipulation guidelines, making promotional claims that the product treats specific systemic diseases or regenerates complex organs violates the homologous use standard.

Clinicians should ensure that:

• Informed Consent is Transparent: Patient consent forms accurately describe the nature of the human tissue allograft, its structural or protective role, and the inherent risks associated with any allogeneic tissue transfer.
• Charting Reflects Homologous Use: Clinical notes should accurately reflect the structural, cushioning, or barrier function being supported by the allograft, rather than utilizing unsubstantiated claims of cellular differentiation.
• Marketing Aligns with Labeling: Website copy, patient brochures, and consultation scripts reviewed by the clinical director must mirror the manufacturer's cleared package insert.

Operationalizing Compliance: Receiving, Storage, and Tracking

Purchasing from a vetted distributor is only the first half of the compliance equation. Once the biologics arrive at the clinic, internal operational workflows dictate whether the practice maintains its compliance posture.

Practice managers should designate a primary and secondary Tissue Coordinator—typically a lead medical assistant or registered nurse—responsible for inventory management. If a product requires cryopreservation or ultra-low temperature storage, the clinic must utilize medical-grade freezers equipped with continuous, automated temperature monitoring and alarm systems. Alternatively, many practices opt for ambient-temperature or refrigerated allograft configurations, or utilize just-in-time shipping per scheduled procedure to eliminate the capital expense and maintenance burden of cryogenic storage.

Every unit must include a unique identification code that links the allograft to the donor record. Your EHR or inventory log must record the tissue ID, manufacturer, expiration date, storage temperature upon receipt, date of implantation/application, and the specific patient identifier. Retaining these records for a minimum of ten years after the date of administration is a standard best practice aligned with federal tissue tracking expectations.

What This Means for Your Practice

Building a defensible biologics program requires structured vendor vetting before a purchase order is ever signed. To implement this framework in your clinic:

1. Audit Current Inventory: Pull the package inserts, FDA registration printouts, and Certificates of Analysis for all human tissue products currently in your facility.
2. Review Practice Marketing: Audit your clinic’s website, social media, and patient intake packets to ensure all descriptions of human tissue allografts avoid unapproved drug or disease-treatment claims.
3. Standardize Vendor Onboarding: Require any prospective biologics supplier to complete your compliance checklist and provide written verification of their tissue bank's FDA 21 CFR Part 1271 registration.
4. Train Clinical Staff: Conduct an in-service training session for receiving staff on cold-chain inspection, tissue logging, and adverse event escalation protocols.

If you are evaluating your current supply chain or adding new procedural options, Dallas Regenerative Solutions (Texas Medical Device Distributor License #1002308) assists practice managers and physicians in sourcing compliant biologics and clinical technologies. Reach out through our contact page to discuss your facility's procurement requirements and request documentation for our product lines.